StreetAlpha
13F holdings · Q3 2026

Tetragon Partners GP

Grand Cayman, E9 · files as Tetragon Partners GP Ltd
Know the moment Tetragon Partners GP filesYou follow Tetragon Partners GP An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1515070

Tetragon Partners GP reported 33 stocks worth $758M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PATH (55.1%), KGEI (5.6%) and SLN (3.5%). Compared with Q2 2026, the fund opened new positions in NBIX, AXSM and UBER, added to PATH, SLN and PHVS, trimmed WK, RLAY and ANNX and sold out of AMLX, ACAD and CUE.

Latest filing: what Tetragon Partners GP did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
5 new16 added5 trimmed4 sold outBought about $112M · sold about $23M
New 5
Added 16
See all 16 →
Trimmed 5
  • ANNX−$2.5M−47%
  • RLAY−$2.2M−22%
  • WK−$1.7M−10%
  • Warner Bros Discov−$1.5M−20%
  • TECX−$459K−42%
Sold out 4

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$758M+23.3% vs last quarter · $766M including options
Stocks held335 new · 4 sold out
Top 5 weight70.3%very concentrated
Turnover18%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
PATH
Uipath Inc
$417M55.1%32.5M+1.6M (+5%)8 of 8
2
KGEI
Kolibri Global Energy Inc
$42.3M5.6%6.8MNo change8 of 8
3
SLN
Silence Therapeutics PLC
$26.6M3.5%2.4M+1.7M (+219%)4 of 8
4
PHVS
Pharvaris N V
$26.6M3.5%838K+543K (+184%)7 of 8
5
IONS
Ionis Pharmaceuticals Inc
$19.7M2.6%441K+344K (+354%)3 of 8
6
AUTL
Autolus Therapeutics PLC
$18.4M2.4%9.5MNo change8 of 8
7
ARWR
Arrowhead Pharmaceuticals in
$17.3M2.3%264K+134K (+102%)5 of 8
8
LYFT
Lyft Inc
$15M2.0%1MNo change8 of 8
9
WK
Workiva Inc
$15M2.0%225K−25K (−10%)6 of 8
10
MBX
Mbx Biosciences Inc
$12.9M1.7%221K+17K (+8%)5 of 8
🔒 23 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
AMLX
Amylyx Pharmaceuticals Inc
$5.4M298K
ACAD
Acadia Pharmaceuticals Inc
$4.2M168K
CUE
Cue Biopharma Inc Com
$3M94K
ACRS
Aclaris Therapeutics Inc
$2.1M400K

Options

valued at the underlying shares
StockTypeValueSharesChange
SLN
Silence Therapeutics PLC
Call$5.5M500K+200,000
AGIO
Agios Pharmaceuticals Inc
Call$1.7M50K0
GLUE
Monte Rosa Therapeutics Inc
Call$1.2M100K+100,000
TENX
Tenax Therapeutics Inc
Call$142K75K0

Reported value

last 8 quarters
$234MQ4 '24
$255MQ1 '25
$354MQ2 '25
$414MQ3 '25
$474MQ4 '25
$509MQ1 '26
$614MQ2 '26
$758MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Tetragon Partners GP 13F FAQ

What does Tetragon Partners GP own?

Tetragon Partners GP reported 33 stocks worth $758M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PATH (55.1%), KGEI (5.6%) and SLN (3.5%). The table above lists every position in the filing (the top 10 without an account).

What did Tetragon Partners GP buy and sell in Q3 2026?

Compared with Q2 2026: 5 new positions, 16 added to, 5 trimmed and 4 sold out. New positions include NBIX, AXSM and UBER. It sold all of AMLX, ACAD and CUE.

When will Tetragon Partners GP file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Tetragon Partners GP's portfolio worth?

The Q3 2026 filing reports $758M in US stocks ($766M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.